Objectives: In this study, our aim is to investigate the effect of CoronaVac vaccine on ovarian reserve in female patients followed up for infertility. Material and methods:Our study is a retrospective study. Forty-six infertile patients who received two doses of CoronaVac vaccine one month apart and had not had a previous Covid 19 infection were included in the study. Anti-müllerian hormone (AMH) and folliculometry of 46 patients one month before CoronaVac vaccine and one month after the second dose of vaccine were compared.Results: There was no statistically significant difference in the change of AMH level and follicle number before and after vaccination (respectively p = 0.366; 0.610). Conclusions:Considering that having a COVID-19 infection has a negative effect on female fertility and causing ovarian damage in recent studies, vaccination is a rational and cost-effective approach to protect ovarian reserve. Knowing that the vaccine does not have a negative effect on fertility may increase the application of the vaccine in women of reproductive age.

Abstract Objective: The aim of this study is; to examine the levels of 25 hydroxy vitamin D (25-OH D), calcium (Ca) and phosphorus (P) in preeclamptic, essential hypertensive and normotensive pregnant groups. Material and Method: A total of 120 pregnant women who came to our clinic for delivery between 35 and 40 weeks of gestation between April 2017 and November 2017 were included in the study. The study group consisted of 40 preeclamptic (n = 40) and 40 essential hypertensive (n = 40), and the control group consisted of 40 normotensive pregnant women (n = 40). The demographic, obstetric and laboratory results of the three groups were compared in terms of 25-OH D levels, calcium and phosphorus levels. Results: Maternal age, BMI and proteinuria were significantly lower in the preeclamptic and essential hypertensive group compared to the control group (p <0.05). Week of gestation was observed to be earlier in the preeclamptic group compared to the other two groups (p <0.05). The mean systolic and diastolic blood pressure of the preeclamptic and essential hypertensive groups were found to be statistically significantly higher than the control group (p <0.05). No statistically significant difference was found between the groups in terms of transaminase. It was found that creatinine in the control group was statistically lower than the average creatinine level in the other two groups (p <0.001). The Blood Urea Nitrogen (BUN) average of the control group was statistically significantly lower than the average of the other two groups (p = 0.001). Phosphorus levels were significantly higher in preeclamptic and essential hypertensive pregnant women compared to normotensive pregnant women (p<0.05). However, no statistically significant difference was found between calcium and 25-OH D levels in all three groups. Conclusion: Low phosphorus level is likely to play a role in the etiology of essential hypertension and preeclampsia. The effects of maternal vitamin D and calcium level on the development of preeclampsia are uncertain, but more extensive research is required on potential positive effects.

AIM This study aims to investigate whether second-trimester fetal adipose tissue components reflect glycemic control in diabetic pregnancies and their role as an auxiliary method in predicting gestational diabetes. MATERIALS AND METHODS This study was designed prospectively, cross-sectionally in 300 pregnant women 24-28 weeks of gestation between April 2020 and July 2020. The adipose tissue thickness of the humerus, femur, scapula, and abdominal circumference was examined by transabdominal ultrasound. The age, body mass index, family history of diabetes, and diabetes history in previous pregnancies of the groups were questioned. RESULTS The anterior abdominal wall adipose tissue thickness of the fetuses we included in the study was 5 ± 0.8 mm, femur adipose tissue thickness was 4 ± 0.7 mm, humerus adipose tissue thickness was 3.7 ± 0.7 mm, scapula adipose tissue thickness was 4.1 ± 2,2 mm. The total adipose tissue thickness was 16.9 ± 2.9 mm. A statistically significant correlation was found between femoral adipose tissue thickness (p = 0.001) and humeral adipose tissue thickness (p = 0.023) in gestational diabetes groups. Patients with a diagnosis of Gestational Diabetes Mellitus (n = 60) constituted the first group, patients without GDM (n =240) constituted the second group. In our independent analysis of two groups, femur and humerus adipose tissue thickness were found to be statistically significantly different between both groups (p= 0.002, p = 0.043, respectively). Other parameters did not differ significantly between groups. Between three groups (healthy, impaired glucose tolerance, and gestational diabetes groups). Femoral adipose tissue thickness was statistically significant among the three groups (p = 0.005). As a result of binary logistic regression, if the femoral adipose tissue thickness was above 4.1 mm, the possibility of developing GDM was observed with 63.8% sensitivity and 65% specificity. CONCLUSION In the prediction of gestational diabetes, fetus femoral adipose tissue thickness may be significant

Background Preterm birth (PTB) is an important cause of neonatal mortality and morbidity. Spontaneous PTB (sPTB) is the most common cause of PTB. In patients with a singleton pregnancy, progesterone treatment appears to reduce the rate of spontaneous preterm birth in those with a previous history of spontaneous preterm labor and/or cervical shortening in the current pregnancy. Progesterone therapies used for the prevention of sPTB may increase the risk of gestational diabetes mellitus (GDM) towards the end of pregnancy owing to their effects on carbohydrate metabolism. Aim We aimed to show the effects of vaginal progesterone use, starting time, and duration of treatment on GDM. Methods A retrospective cohort study was carried out in pregnant women 18 to 39 years old who came to our hospital between January 1, 2021, and August 31, 2021, and who had a 2-hour 75-g oral glucose tolerance test (OGTT) at 24 to 28 weeks of gestation. In a total of 540 patients, 68 were diagnosed with GDM based on at least one abnormal plasma glucose value at screening. The remaining 472 patients with normal plasma glucose levels were considered as the control group. The groups were compared in terms of age, parity, pre-pregnancy body mass index (BMI), smoking, gestational age, and vaginal progesterone use. Patients using vaginal progesterone with and without GDM were then compared again in terms of indications for vaginal progesterone use, initiation time of progesterone therapy, duration of progesterone use, and cervical length. Results The incidence of GDM in our study group was 12.5%. Despite the use of vaginal progesterone at a higher rate in the GDM group than in the control group (23.5 vs. 13.9%; p=0.07), it was not statistically significant. When we examined patients using progesterone as a subgroup analysis, the mean time to start vaginal progesterone treatment was 19.8±2.6 (14–24), and it was significantly earlier in the GDM group (18.1±2.0 vs. 20.2±2.6; p=0.007). Initiation of vaginal progesterone before 20 weeks of gestation was statistically significantly more frequent in the GDM group than the control group (68.8 vs. 39.4%; p=0.050 OR :3.3, 95%CI: 1.0–10.8). The mean duration of vaginal progesterone use was 50.0±15.6 days (28–90) and it was longer in the GDM group (57.8±13.4 vs. 48.1±15.6; p=0.027). Conclusion Since the duration of vaginal progesterone use will be prolonged, there may be a risk of GDM, especially in patients who started vaginal progesterone before the 20th week of pregnancy. Even if the OGTT test performed between 24–28 weeks is normal, it should be kept in mind that these patients may have GDM in the later weeks of pregnancy, and repeating the OGTT test should be considered if necessary.